Literature DB >> 31523374

Two Chinese nephronophthisis pedigrees harbored a compound heterozygous deletion with a point mutation in NPHP1.

Huamu Chen1,2, Hongrong Lin1, Zhihui Yue1, Haiyan Wang3, Junhui Yang4, Liangzhong Sun1,2.   

Abstract

NPHP1 is the most prevalent genetic factor in the development of juvenile nephronophthisis (NPHP). In our previous study, NPHP1 homozygous point mutations were detected by Sanger sequencing in three cases from two nonconsanguineous pedigrees. However, mutant sites were detected in only one parent from each respective pedigree. To investigate whether other disease-causing mutations were present, targeted exome sequencing (TES) of 63 ciliopathy genes was performed in the probands of the two pedigrees. In addition to the previously detected point mutations, a complete heterozygous deletion of NPHP1 (1-20 exons) in the other allele was found in each of the three patients. The deletions were inherited from one parent of each pedigree. These is the first report of Chinese NPHP patients harboring a complete heterozygous deletion of NPHP1 in one allele and a point mutation in the other one. The study demonstrated that TES is helpful in identifying complicated mutations in patients with NPHP.

Entities:  

Keywords:  NPHP1; Nephronophthisis; heterozygous deletion; targeted exome sequencing

Year:  2019        PMID: 31523374      PMCID: PMC6737400     

Source DB:  PubMed          Journal:  Int J Mol Epidemiol Genet        ISSN: 1948-1756


  2 in total

1.  Clinical and pathological features of immune-mediated necrotising myopathies in a single-centre muscle biopsy cohort.

Authors:  Hongxia Yang; Xiaolan Tian; Lining Zhang; Wenli Li; Qingyan Liu; Wei Jiang; Qinglin Peng; Guochun Wang; Xin Lu
Journal:  BMC Musculoskelet Disord       Date:  2022-05-06       Impact factor: 2.562

2.  A case report of NPHP1 deletion in Chinese twins with nephronophthisis.

Authors:  Feng Chen; Limeng Dai; Jun Zhang; Furong Li; Jinbo Cheng; Jinghong Zhao; Bo Zhang
Journal:  BMC Med Genet       Date:  2020-04-19       Impact factor: 2.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.